Online citations, reference lists, and bibliographies.
← Back to Search

Radical Multimodality Therapy For Malignant Pleural Mesothelioma.

O. Abdel-Rahman, Z. El-Sayed, H. Mohamed, Mostafa Eltobgy
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Malignant pleural mesothelioma is an almost always fatal tumour, for which palliative platinum-based chemotherapy is currently the standard treatment. Multimodal therapeutic strategies incorporating surgery, radiation therapy or photodynamic therapy and chemotherapy have been recommended for selected patients but there is no consensus about their effectiveness. OBJECTIVES To assess the benefits and harms of radical multimodal treatment options (including radical surgery ± radical radiotherapy ± photodynamic therapy ± systemic therapy) compared to each other or to palliative treatments, for people with malignant pleural mesothelioma. SEARCH METHODS We reviewed data from the Cochrane Lung Cancer group's Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase. We also checked reference lists of primary original studies, review articles and relevant conference proceedings manually for further related articles up to 21 March 2017. SELECTION CRITERIA We included parallel-group randomised controlled trials of multimodal therapy for people with malignant pleural mesothelioma (stages I, II or III) that measured at least one of the following endpoints: overall survival, health-related health-related quality of life, adverse events or progression-free survival. We considered studies regardless of language or publication status. DATA COLLECTION AND ANALYSIS Two review authors independently extracted relevant information on participant characteristics, interventions, study outcomes, and data on the outcomes for this review, as well as information on the design and methodology of the studies. Two review authors assessed the risk of bias in the included trials using pre-defined 'Risk of bias' domains. We assessed the methodological quality using GRADE. MAIN RESULTS We conducted this review in accordance with the published Cochrane protocol. Two randomised clinical trials with 104 participants fulfilled our inclusion criteria. Both trials were at high risk of bias (for outcomes other than overall survival), and we rated the evidence as moderate quality for overall survival and low quality for all other outcomes. One trial compared combined extrapleural pneumonectomy (EPP) plus neoadjuvant platinum-based chemotherapy plus postoperative high-dose hemithoracic radiotherapy with combined EPP plus platinum-based chemotherapy. The other trial compared EPP plus postoperative hemithoracic radiotherapy with standard (non-radical) therapy alone following platinum-based chemotherapy (patients in the standard therapy arm received continued oncological management according to local policy, which could include further chemotherapy or palliative radiotherapy).For the first trial, median overall survival calculated from registration was 20.8 months (95% confidence interval (CI) 14.4 to 27.8) in the no-radiotherapy group and 19.3 months (95% CI 11.5 to 21.8) in the radiotherapy group. For the second trial, median overall survival was 14.4 months (95% CI 5.3 to 18.7) for patients allocated to EPP and 19.5 months (95% CI 13.4 to time not yet reached) for patients randomised to standard non-radical therapy. In the second trial, 12 serious adverse events were reported during the study period: ten in the EPP group and two in the non-radical therapy group. Overall health-related quality of life scores were not different between the two arms in either study. We could not perform a meta-analysis of the two included trials due to clinical heterogeneity. We also identified three ongoing trials evaluating the topic of our review. AUTHORS' CONCLUSIONS The overall strength of the evidence gathered in this review is low and there is a lack of available evidence to support the use of radical multimodality therapy in routine clinical practice (particularly as one trial suggests greater harm). Given the added cost of multimodality treatment and the possible increase in risk of adverse effects, the lack of evidence of their effectiveness probably means that these interventions should currently be limited to clinical trials alone.
This paper references
10.1016/S0093-7754(03)00283-5
Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.
C. Manegold (2003)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1002/14651858.CD012541
Radiation therapy for preventing instrumentation track metastases in malignant pleural mesothelioma
Jacques Eastment (2017)
10.1093/jjco/hyn145
A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma.
T. Yamanaka (2009)
10.1016/j.jtho.2015.11.005
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
F. Galateau-Sallé (2016)
10.1136/bmj.315.7121.1533
Meta-analysis: Principles and procedures
M. Egger (1997)
Mesothelioma Research Fund, and Guy’s and St Thomas’ NHS Foundation Trust. We contacted the corresponding author by email (15 April 2017) for some clarifications about adverse events
June Hancock (2017)
10.1016/J.IJROBP.2006.03.012
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
A. Allen (2006)
10.1179/joc.2008.20.3.348
Participation of Omi Htra2 Serine-Protease Activity in the Apoptosis Induced by Cisplatin on SW480 Colon Cancer Cells
F. Pruefer (2008)
10.1002/SIM.1186
Quantifying heterogeneity in a meta-analysis.
J. Higgins (2002)
10.1586/17476348.2016.1171147
The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence
P. Bertoglio (2016)
10.1016/j.lungcan.2013.11.004
Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review.
N. Macleod (2014)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1007/s00428-014-1664-9
Reproducibility of histological subtyping of malignant pleural mesothelioma
L. Brcic (2014)
Mesothelioma: a review.
F. Mott (2012)
10.1016/j.lungcan.2017.09.015
Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma.
O. Abdel-Rahman (2017)
10.6004/JNCCN.2012.0181
Photodynamic therapy for malignant pleural mesothelioma.
J. Friedberg (2012)
10.1097/JTO.0000000000000499
Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial
N. Macleod (2015)
10.1016/J.LUNGCAN.2007.02.004
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
10.1378/CHEST.112.4_SUPPLEMENT.272S
Multimodality therapy for malignant pleural mesothelioma.
D. Sugarbaker (1997)
Extended pleurectomydecortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival
JS Friedberg 2017 Friedberg (2017)
10.1097/JTO.0b013e31828353d7
Surgery in mesothelioma--where do we go after MARS?
B. Hiddinga (2013)
10.1016/j.canep.2015.08.007
The next mesothelioma wave: mortality trends and forecast to 2030 in Brazil.
E. Algranti (2015)
10.1016/j.jtho.2016.09.124
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
V. Rusch (2016)
10.2174/1871520617666170102151918
Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials.
Hadeer I. Mohamed (2017)
10.1016/j.athoracsur.2016.08.071
Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.
J. Friedberg (2017)
10.1586/17476348.2015.1083426
Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review
O. Abdel-Rahman (2015)
10.3978/j.issn.2225-319X.2012.11.04
Malignant pleural mesothelioma: an epidemiological perspective.
Benjamin M. Robinson (2012)
10.1016/S2213-2600(15)00092-2
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
10.1016/j.critrevonc.2010.04.004
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
10.1371/journal.pone.0145039
Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients
E. Taioli (2015)
10.1016/S1077-9108(08)79041-8
Malignant Pleural Mesothelioma: Surgical Management in 285 Patients
P. Bejarano (2009)
10.1002/14651858.CD003880.PUB4
Radiotherapy for malignant pleural mesothelioma.
E. Chapman (2006)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1016/S1470-2045(15)00208-9
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
R. Stahel (2015)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1007/s00066-016-1092-7
Role of postoperative radiotherapy in the management of malignant pleural mesothelioma
O. Abdel-Rahman (2016)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1120/jacmp.v17i2.5980
A pilot study of volumetric‐modulated arc therapy for malignant pleural mesothelioma
L. Runxiao (2016)
Peritoneal mesothelioma: a review.
A. Bridda (2007)
10.3978/j.issn.2225-319X.2012.11.07
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.
C. Cao (2012)
10.1136/bmj.b2535
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
D. Moher (2009)
10.1016/j.lungcan.2013.08.005
Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
S. Armato (2013)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1007/978-0-387-78665-0_5620
European Organization for Research and Treatment of Cancer
V. Preedy (2010)
10.1097/JTO.0b013e318211127a
Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid Mesothelioma
Kyuichi Kadota (2011)
10.1111/nyas.12180
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
J. Wolchok (2013)
Radical multimodality therapy for malignant pleural mesothelioma
Z Elsayed (2017)
10.1120/jacmp.v17i2.5980
A pilot study of volumetric-modulated arc therapy for malignant pleural mesothelioma.
L. Runxiao (2016)
10.1002/JSO.2930600207
Optimal management of malignant mesothelioma after subtotal pleurectomy: Revisiting the role of intrapleural chemotherapy and postoperative radiation
E. Sauter (1995)
10.2214/AJR.172.4.10587144
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
R. Heelan (1999)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1007/BF02303746
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
H. Pass (2006)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
A case of pancreatic lymphoma.
M. Piesman (2007)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.3390/cancers8090083
Prospects in the Application of Photodynamic Therapy in Oral Cancer and Premalignant Lesions
Rajan Saini (2016)
10.1016/j.jtcvs.2015.09.129
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2016)
10.1002/9780470712184
Cochrane Handbook for Systematic Reviews of Interventions
J. P. Higgins (2019)
10.1002/SIM.698
A comparison of methods to detect publication bias in meta-analysis.
P. Macaskill (2001)
10.2486/INDHEALTH.45.379
Malignant mesothelioma: global incidence and relationship with asbestos.
C. Bianchi (2007)
World Health Organization Committee for Tumors of the Pleura. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances
A Churg (2004)



This paper is referenced by
10.21037/shc.2018.06.06
Induction or adjuvant chemotherapy for radical multimodality therapy
Annabel J Sharkey (2018)
10.1101/2020.01.07.898122
ALPPL2 is a highly specific and targetable tumor cell surface antigen
Yang Su (2020)
Multimodality treatment of malignant pleural mesothelioma
Schil (2019)
10.1093/ejcts/ezaa158
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
10.21037/tlcr.2018.10.02
Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations.
Charlotte De Bondt (2018)
10.1021/acsomega.0c02288
Hairpin Oligonucleotide Can Functionalize Gold Nanorods for in Vivo Application Delivering Cytotoxic Nucleotides and Curcumin: A Comprehensive Study in Combination with Near-Infrared Laser
Upasana Das (2020)
10.5603/ARM.2019.0051
Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm.
M. Sayan (2019)
10.21608/resoncol.2018.4306.1062
Four versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelima: Results of a Randomized Phase II Study
A. Nagy (2018)
10.1158/0008-5472.CAN-20-1418
ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen
Yang Su (2020)
10.1120/jacmp.v17i2.5980
A pilot study of volumetric‐modulated arc therapy for malignant pleural mesothelioma
L. Runxiao (2016)
10.21037/tlcr.2018.05.07
A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).
Jo Raskin (2018)
10.1016/j.lungcan.2017.09.015
Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma.
O. Abdel-Rahman (2017)
10.1111/crj.12778
Global trends in mortality from malignant mesothelioma: Analysis of WHO mortality database (1994‐2013)
O. Abdel-Rahman (2018)
10.3389/fonc.2018.00091
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
Marika Rossini (2018)
10.1080/17476348.2019.1607300
The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma
K. Shohdy (2019)
10.1053/j.jvca.2020.07.017
The 2019 ERS/ESTS/EACTS/ESTRO Guidelines on the Management of Patients With Malignant Pleural Mesothelioma.
T. Gelzinis (2020)
10.21037/tlcr.2019.11.23
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.
S. Gray (2020)
10.12688/f1000research.15796.1
Multimodality treatment of malignant pleural mesothelioma
L. Berzenji (2018)
10.1183/13993003.00953-2019
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
10.1007/978-3-030-16884-1_15
Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma
L. Gianoncelli (2019)
Semantic Scholar Logo Some data provided by SemanticScholar